Krish Krishnan News Today

Operator: Thank you for standing by and welcome to the Krystal Biotech Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are on a lesson-only mode.

Operator: Thank you for standing by and welcome to the Krystal Biotech Third Quarter 2023 Earnings Conference Call. As a reminder today’s conference call is being recorded.

Cantor Fitzgerald said it expects a “very strong product launch” of a gene therapy made by Krystal Biotech, the topical gel Vyjuvek which treats a rare skin disease.

PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company fo...

By Denny Jacob Krystal Biotech shares tumbled 10% to $111.67 following a wider loss in its latest quarter. The stock is up 42% on the year. The...

Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) and Krystal Biotech (NASDAQ:KRYS – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Volatility & Risk Adaptive Biotechnologies has a beta of 1.18, […]

Krystal Biotech (NASDAQ:KRYS – Get Rating) and Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability. Profitability This table compares Krystal Biotech and Neurocrine Biosciences’ […]

FDA Approval, Private Placement Funding Buoy Biotech Firm

The U.S. Food and Drug Administration recently approved a treatment called Vyjuvek – the first gene therapy for sale that is applied to the outside of a patient's body. The treatment, [...]

About 9,000 to 10,000 people suffer from dystrophic epidermolysis bullosa globally